期刊文献+

Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells 被引量:3

Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells
下载PDF
导出
摘要 Bisphenol-A(BPA) has been considered as an endocrine disrupting chemical(EDC) because it can exert estrogenic properties.For bisphenol-S(BPS) and bisphenol-F(BPF) that are BPA analogs and substitutes,their risk to estrogendependent cancer has been reported rarely compared with the numerous cases of BPA.In this study,we examined whether BPA,BPS,and BPF can lead to the proliferation,migration,and epithelial mesenchymal transition(EMT) of MCF-7 clonal variant(MCF-7 CV) breast cancer cells expressing estrogen receptors(ERs).In a cell viability assay,BPA,BPS,and BPF significantly increased proliferation of MCF-7 CV cells compared to control(DMSO) as did17β-estradiol(E2).In Western blotting assay,BPA,BPS,and BPF enhanced the protein expression of cell cycle progression genes such as cyclin D1 and E1.In addition,MCF-7 CV cells lost cell to cell contacts and acquired fibroblast-like morphology by the treatment of BPA,BPS,or BPF for 24 hours.In cell migration assay,BPA,BPS,and BPF accelerated the migration capability of MCF-7 CV cells as did E2.In relation with the EMT process,BPA,BPS,and BPF increased the protein expression of N-cadherin,while they decreased the protein expression of Ecadherin.When BPA,BPS,and BPF were co-treated with ICI 182,780,an ER antagonist,proliferation effects were reversed,the expression of cyclin D1 and cyclin E1 was downregulated,and the altered cell migration and expression of N-cadherin and E-cadherin by BPA,BPS,and BPF were restored to the control level.Thus,these results imply that BPS and BPF also have the risk of breast cancer progression as much as BPA in the induction of proliferation and migration of MCF-7 CV cells by regulating the protein expression of cell cycle-related genes and EMT markers via the ER-dependent pathway. Bisphenol-A(BPA) has been considered as an endocrine disrupting chemical(EDC) because it can exert estrogenic properties.For bisphenol-S(BPS) and bisphenol-F(BPF) that are BPA analogs and substitutes,their risk to estrogendependent cancer has been reported rarely compared with the numerous cases of BPA.In this study,we examined whether BPA,BPS,and BPF can lead to the proliferation,migration,and epithelial mesenchymal transition(EMT) of MCF-7 clonal variant(MCF-7 CV) breast cancer cells expressing estrogen receptors(ERs).In a cell viability assay,BPA,BPS,and BPF significantly increased proliferation of MCF-7 CV cells compared to control(DMSO) as did17β-estradiol(E2).In Western blotting assay,BPA,BPS,and BPF enhanced the protein expression of cell cycle progression genes such as cyclin D1 and E1.In addition,MCF-7 CV cells lost cell to cell contacts and acquired fibroblast-like morphology by the treatment of BPA,BPS,or BPF for 24 hours.In cell migration assay,BPA,BPS,and BPF accelerated the migration capability of MCF-7 CV cells as did E2.In relation with the EMT process,BPA,BPS,and BPF increased the protein expression of N-cadherin,while they decreased the protein expression of Ecadherin.When BPA,BPS,and BPF were co-treated with ICI 182,780,an ER antagonist,proliferation effects were reversed,the expression of cyclin D1 and cyclin E1 was downregulated,and the altered cell migration and expression of N-cadherin and E-cadherin by BPA,BPS,and BPF were restored to the control level.Thus,these results imply that BPS and BPF also have the risk of breast cancer progression as much as BPA in the induction of proliferation and migration of MCF-7 CV cells by regulating the protein expression of cell cycle-related genes and EMT markers via the ER-dependent pathway.
出处 《The Journal of Biomedical Research》 CAS CSCD 2017年第4期358-369,共12页 生物医学研究杂志(英文版)
基金 supported by a grant from the NextGeneration BioGreen 21 Program(no.PJ011355-2015) supported by Priority Research Centers Program through NRF funded by the Ministry of Education,Science and Technology (2015R1A6A1A04020885)
关键词 human breast cancer cells endocrine disrupting chemicals bisphenol-A bisphenol-S bisphenol-F epithelial-mesenchymal transition migration human breast cancer cells endocrine disrupting chemicals bisphenol-A bisphenol-S bisphenol-F epithelial-mesenchymal transition migration
  • 相关文献

参考文献1

二级参考文献38

  • 1American Cancer Society American Cancer Society: Cancer Facts and Figures 2015. Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. Bone cancer pain[J]. Ann N YAcadSci, 2010,1198:173-181.
  • 2Hart CA, Brown M, Bagley S, et al. lnvasive characteris- tics of human prostatic epithelial cells: understanding the metastatic process[J]. Br J Cancer, 2005,92:503-512.
  • 3Wang N, Docherty FE, Brown HK, et al. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models[J]. J Bone Miner Res, 2014,29( 12):2688-2696.
  • 4Sun YX, Schneider A, lung Y, et al. Skeletal localization and neutralization of the SDF-I (CXCL 12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo[J]. J Bone Miner Res, 2005,20(2):318-329.
  • 5Miwa S, Mizokami A, Keller ET, et al. The bisphospho- nate YM529 inhibits osteolytic and osteoblastic chang- es and CXCR-4-induced invasion in prostate cancer[l]. Cancer Res, 2005,65( 19):8818-8825.
  • 6Fidler II. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited[J]. Nat Rev Cancer, 2003, 3(6):453-458.
  • 7Duda DG, Kozin SV, Kirkpatrick ND, et al. CXCL12 (SDFlalpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?[J] Clin Cancer Res, 2011,17(8):2074-2080.
  • 8Sun X, Cheng G, Hao M, et al. CXCLI2/CXCR4/CXCR7 chemokine axis and cancer progression[J]. Cancer Metastasis R ev, 2010,29(4):709-722.
  • 9Muller A, Homey B, Soto H, et al. Involvement of chemo- kine receptors in breast cancer metastasis[J]. Nature, 2001,410(6824):50-56.
  • 10Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/ SDF-I chemokine axis: a potential therapeutic target for bone metastases?[J] Curt Pharm Des', 2010,16(11): 1284-1290.

共引文献4

同被引文献13

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部